Prof Jan van Meerbeeck, discuses his research into the use of monoclonal antibodies to treat mesothelioma, a disease generally seen in professionally exposed individuals. Professor van Meerbeeck speaks about the future of lung cancer treatment and predicts a greater emphasis on individualised and targeted treatments.